Focused research and development in biopharmaceuticals

「Following major progress toward the practical application of SHED, the Group redefined cerebral palsy as the most important indication in its cell therapy business and decided to strategically concentrate management resources on this indication.」

「The Group operates two businesses. The company conducts the development of biosimilars and the supply of active pharmaceutical ingredients and finished products after the products are launched, collectively referred to below as “biosimilar APIs, etc.,” through its “biosimilars business.” Its wholly owned subsidiary S-Quatre Co., Ltd. (referred to below as “S-Quatre”) operates the “cell therapy business (regenerative medicine),” seeking to commercialize regenerative medicine products using deciduous tooth dental pulp stem cells independently developed by S-Quatre (referred to below as “SQ-SHED”; SHED is an acronym for Stem cells from Human Exfoliated Deciduous teeth). Following discussions based on the management policy of investing finite management resources strategically and intensively, the novel biopharmaceuticals business, which had been operated since the company's founding, has focused exclusively since fiscal 2023 on business development activities to further advance research at external institutions based on research results already acquired.」

「We have decided to allocate the management resources previously spread across three businesses strategically and intensively to the biosimilars business, which provides a stable earnings base, and selected pipelines in the cell therapy business (regenerative medicine), which provides a basis for growth. The novel biopharmaceuticals business is focusing exclusively on business development activities to further advance research at external institutions based on research results already acquired.」

「Through this newly established company split, the company will center its operations on the biosimilars business, while the newly established company will be a single-business company specializing in cell therapy. This will enable both organizations to further optimize management resources, diversify their financing methods in line with the characteristics of each business and accelerate the growth of each business.」

「To achieve the above objectives, we are advancing R&D activities centered on three principal businesses: biosimilars, novel biopharmaceuticals and cell therapy (regenerative medicine).」

「To achieve the above objectives, we are advancing R&D activities centered on three principal businesses: biosimilars, novel biopharmaceuticals and cell therapy (regenerative medicine).」

「Specifically, while establishing a stable earnings base through the biosimilars business, we are pursuing growth through the novel biopharmaceuticals business and the cell therapy business (regenerative medicine).」

「Our management strategy is to define biopharmaceuticals, represented by antibody drugs, as the field of R&D and establish three core businesses: the novel biopharmaceuticals business, which develops drug candidates identified through research at universities and other institutions; the biosimilars business, a new category that can be described as the generic-drug category for biopharmaceuticals; and the cell therapy business (regenerative medicine), centered on regenerative medicine and intended to expand high-growth businesses for the future.」

「The progress of each business during the cumulative third quarter of the current consolidated fiscal year was as follows: ① Biosimilars business ② Novel biopharmaceuticals business ③ New biotechnology business」

「We are steadily generating revenue from sales of the active pharmaceutical ingredient for the neutropenia treatment filgrastim BS supplied by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd., as well as royalty income based on sales of a darbepoetin alfa biosimilar jointly developed with Sanwa Kagaku Kenkyusho Co., Ltd., which began sales on 27 November 2019. We are also steadily advancing development activities for other pipeline products under development.」

「Specifically, while establishing a stable earnings base through the biosimilars business, we are pursuing growth through the novel biopharmaceuticals business and the new biotechnology business, centered on cell therapy in regenerative medicine.」

「Specifically, while establishing a stable earnings base through the biosimilars business, we are pursuing growth through the novel biopharmaceuticals business and the new biotechnology business, centered on cell therapy in regenerative medicine.」

「Our management strategy is to define biopharmaceuticals, represented by antibody drugs, as the field of R&D and establish three core businesses: the novel biopharmaceuticals business, which develops drug candidates identified through research at universities and other institutions; the biosimilars business, a new category that can be described as the generic-drug category for biopharmaceuticals; and the new biotechnology business, centered on regenerative medicine and intended to expand high-growth businesses for the future.」

「Specifically, while establishing a stable earnings base through the biosimilars business, we will pursue growth through the novel biopharmaceuticals business and the new biotechnology business, centered on cell therapy in regenerative medicine.」

「Specifically, while establishing a stable earnings base through the biosimilars business, we will pursue growth through the novel biopharmaceuticals business and the new biotechnology business, centered on cell therapy in regenerative medicine.」

「Focusing on biopharmaceuticals, a market expected to expand, we are engaged in drug development through three core businesses: biosimilars, novel biopharmaceuticals and new biotechnology.」

「We are actively pursuing the steady development of existing candidates and launching new development programs.」

「Focusing on biopharmaceuticals, a market expected to expand, we are engaged in drug development through three core businesses: biosimilars, novel biopharmaceuticals and new biotechnology.」

「To deliver higher-quality, lower-cost biopharmaceuticals to more patients accurately and promptly while achieving further growth for the company, we are actively pursuing the steady development of existing candidates and launching new development programs as follows.」

「Our management strategy is to define biopharmaceuticals, represented by antibody drugs, as the field of R&D and pursue this through two businesses: the novel biopharmaceuticals business, which develops drug candidates identified through research at universities and other institutions, and the biosimilars business, which can be described as the generic-drug category for biopharmaceuticals.」

「For the time being, our policy is to concentrate management resources on biosimilars, whose R&D risk is clearly lower than that of new drugs.」

「For the time being, our policy is to concentrate management resources on biosimilars, whose R&D risk is clearly lower than that of new drugs.」

「For the time being, our policy is to concentrate management resources on biosimilars, whose R&D risk is clearly lower than that of new drugs.」

「Focusing on biopharmaceuticals, a market expected to expand, we are engaged in drug development through two core businesses: the biosimilars business and the novel biopharmaceuticals business.」